

Overview of CML related sessions at EHA 2023 Hybrid Congress

June 8-11, 2023 (Live streamed program)

June 14-15 (Virtual days)

Time slots	Sessions
Live streamed sessions	
June 8 (Thursday) 10.15 – 11.45 CEST Room: Panorama 1	<p>Satellite Symposium: (Supported by Novartis) Chronic myeloid leukemia is not solved: Transforming treatment expectations and patient outcomes</p> <p>Chair: Timothy Hughes (Australia)</p> <p>Program:</p> <ul style="list-style-type: none"> • Chronic myeloid leukemia is not solved – Stories from frontline of treatment (L. Machado, Canada) • Patient and physician perspectives: Are we meeting the goals of treatment in newly diagnosed CML (S. Saussele, Germany) • Redefining standard of care for newly diagnosed patients: insights into the latest therapeutic developments (T. Hughes, Australia) • Later-line treatment success: How novel agents are transforming CML treatment expectations (J. Valentin García-Gutiérrez, Spain) • A new era of CML therapy: What can we take home to clinical practice across all lines of therapy (all faculty)
June 9 (Friday) 8.00 – 9.30 CEST Room: Hall Boiron	<p>Education Session: Chronic myeloid leukemia</p> <p>Chair: Dragana Milojkovic (UK)</p> <p>Program:</p> <ul style="list-style-type: none"> • What can we learn from single cell studies in CML? (T. Ong, Singapore) • How to improve eligibility and success of TFR in CML (M. Breccia, Italy) • Late line treatment in chronic phase (A. Hochhaus, Germany)

Time slots	Sessions
June 9 (Friday) 9.45 – 10.45 CEST Room: Panorama 1	ELN-EHA SWG for CML: CML modelling the future Chair: Jane Apperley (UK) Program: <ul style="list-style-type: none"> • Therapeutic opportunities of allosteric BCR::ABL1 inhibitors (O. Hantschel, Germany) • Dissecting phylogenetic trees in CML (A. Kamizela, UK) • Drug profiling for CML blast crisis (S. Mustjoki, Finland)
Advocacy & Patient Sessions	
June 9 (Friday) 8.00 – 9.30 CEST Room: Illusion	EHA-Patient Joint Symposium Session I: Novel clinical trials in hematology – the comparator challenge and the need for new formats Chairs: <ul style="list-style-type: none"> • Jan Geissler (Germany) • Martin Kaiser (UK)
June 9 (Friday) 10.00 – 11.15 CEST Room: Illusion	EHA-Patient Joint Symposium Session II: Optimizing treatment and appraisals Chairs: <ul style="list-style-type: none"> • Zack Pemberton-Whiteley (UK) • Marie José Kersten (The Netherlands)
Oral Presentations	
CML biology and translational	<ul style="list-style-type: none"> • S150: TIMING AND CLONAL TRAJECTORY TO CHRONIC MYELOID LEUKAEMIA DRIVEN BY THE PHILADELPHIA CHROMOSOME (Kamisela A et al.)

Time slots	Sessions
<p>research</p> <p>June 9 (Friday)</p> <p>14.45 – 16.00</p> <p>CEST</p> <p>Room: Harmonie 2</p>	<ul style="list-style-type: none"> • S151: COMBINATION OF LARGE SPLEEN AND LOW <i>IN VIVO</i> KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA (Hughes T et al.) • S152: COMBINATORY THERAPY OF ASCIMINIB AND PONATINIB WAS EFFECTIVE IN THE TREATMENT OF BLAST PHASE CML CDX MODEL (Čuřík N et al) • S153: MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS (Cuenca Zamora EJ et al.) • S154: IDENTIFICATION OF NOVEL FACTORS CONTROLLING NON GENETIC CELL PLASTICITY IN CHRONIC MYELOID LEUKEMIA (Baselli G et al.)
<p>Evolution of clinical management in CML</p> <p>June 11 (Sunday)</p> <p>11.30 – 12.45</p> <p>CEST</p>	<ul style="list-style-type: none"> • S155: PROGNOSTIC FACTORS FOR 3-YEAR MAJOR MOLECULAR RESPONSE MAINTENANCE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN THE EUROPEAN STOP KINASE INHIBITORS (EURO-SKI) TRIAL (Pfirmsmann M et al.) • S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL (Ernst T et al.) • S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ALPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ALPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL (Hochhaus A et al.) • S158: EFFICACY OF LOW-DOSE TYROSINE KINASE INHIBITOR THERAPY AFTER ACHIEVING MAJOR MOLECULAR RESPONSE IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA (Jiang Q et al) • S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY (Efficace F et al.)
e-Posters	
<p>CML – Biology and Translational</p>	<ul style="list-style-type: none"> • P655: LIMITATIONS OF USING CD26+ LEUKEMIA STEM CELL QUANTITATION IN CML

Time slots	Sessions
Research	<p>PATIENTS TO ASSESS RESIDUAL LEUKEMIA CLONE (Kapranov N et al.)</p> <ul style="list-style-type: none"> • P660: NEXT-GENERATION SEQUENCING (NGS) FOR DETECTING BCR::ABL-INDEPENDENT MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH RESISTANCE TO TYROSINE KINASE INHIBITOR TREATMENT (Kustova D et al.)
CML - Clinical	<ul style="list-style-type: none"> • P673: ASCIMINIB MANAGEMENT IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH T315I MUTATION (Kuzmina E et al.) • P677: THE FACTORS OF LATE MOLECULAR RELAPSES AFTER TYROSINE KINASE INHIBITORS DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Petrova A et al.) • P682: THE RESULTS OF THE RUSSIAN PROSPECTIVE STUDY OF REDUCTION AND DISCONTINUATION TREATMENT OF TKI (READIT-2020) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE (Gurianova M et al.)
Poster presentations	
<p>CML – Biology and Translational Research</p> <p>June 9 (Friday)</p> <p>18.00 – 19.00 CEST</p> <p>Room: Poster area</p>	<ul style="list-style-type: none"> • P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS (Jacobi H et al.) • P654: ALLELIC POLYMORPHISMS OF KIRS AND HLAS PREDICT FAVORABLE ACHIEVEMENT OF TREATMENT-FREE REMISSION IN CML: RESULTS FROM THE POKSTIC TRIAL, MULTICENTER RETROSPECTIVE OBSERVATIONAL STUDY (Ureshino H et al.) • P656: NOVEL THIAZOLIDINEDIONE WITH HDAC INHIBITING PROPERTIES OPTIMIZED FOR CHRONIC MYELOID LEUKEMIA TREATMENT (Rams A et al.) • P657: PATHOGENESIS OF TYROSINE KINASE INHIBITOR–ASSOCIATED VASCULAR TOXICITY IN CHRONIC MYELOID LEUKEMIA (Proaktor AG et al.) • P658: DEVELOPMENT OF THE HIGHLY ACCURATE AND SENSITIVE METHOD USING THE CHIP-BASED DIGITAL PCR (LOAA) FOR THE DETECTION OF BCR::ABL1 TRANSCRIPTS DURING WHOLE PERIOD OF CHRONIC MYELOID LEUKEMIA TREATMENT (Song H-W et al.) • P659: BUPARLISIB A PROMISING THERAPEUTIC APPROACH IN CHRONIC MYELOID

Time slots	Sessions
	<p>LEUKEMIA RESISTANT TO IMATINIB (Ribeiro A et al.)</p> <ul style="list-style-type: none"> P661: EFFECT OF VITAMIN K2 ON COVID-19 S1 PROTEIN-INDUCED CYTOTOXICITY AGAINST HUVECS AND ON THE ACTION OF ASCIMINIB IN ABELSON-TYROSINE-KINASE-INHIBITOR-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA CELLS (Okabe S et al.)
<p>CML – Clinical June 9 (Friday) 18.00 – 19.00 CEST Room: Poster area</p>	<ul style="list-style-type: none"> P662: POST HOC ANALYSIS OF PATIENT RESPONSES BY T315I MUTATION STATUS FROM THE 3-YEAR UPDATE OF THE OPTIC TRIAL: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (Cortes J et al.) P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL (Breccia M et al.) P664: REAL-WORLD ANALYSIS OF MUTATION CHARACTERISTICS AND CLINICAL OUTCOMES IN 343 CHRONIC MYELOID LEUKEMIA PATIENTS WITH BCR::ABL KINASE DOMAIN MUTATIONS (Hu S et al.) P665: RAPID AND DEEP RESPONSES WITH ASCIMINIB IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) IN THE PHASE 3 ASCEMBL STUDY (Hughes T et al.) P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): A PROSPECTIVE RANDOMIZED CONTROLLED STUDY (Weiming L et al.) P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY (Gambarcorti-Passerini C et al.) P668: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING (Lang F et al.) P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE (Semerad L et al.) P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB

Time slots	Sessions
	<p>TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA (Müller MC et al.)</p> <ul style="list-style-type: none"> • P671: USE OF RT-QPCR VERSUS DIGITAL DROPLET PCR AND EVALUATION OF CD26+ CELLS IN LONG TFR PATIENTS WITH CHRONIC MYELOID LEUKEMIA (De Fazio L et al.) • P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES (Haddad F et al.) • P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL (Le Coutre P et al.) • P675: IMATINIB THERAPY IN PREVIOUSLY UNTREATED CHRONIC MYELOID LEUKAEMIA PATIENTS WHO ACHIEVE MMR AFTER 12 MONTHS THERAPY WITH DASATINIB: A STRATEGY TO AVOID LONG TERM OFF TARGET TOXICITY (Pemberton L et al.) • P676: UPDATED RESULTS FROM THE TRIAL ITCC-054/COG-AAML1921: BOSUTINIB IN NEWLY DIAGNOSED AND RESISTANT/INTOLERANT PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Brivio E et al.) • P678: EARLY WARNING RESPONSES IN CML PATIENTS: A REAL-LIFE TURIN EXPERIENCE (Giai V et al.) • P679: SPOTLIGHT ON THE REAL-WORLD TREATMENT OF CML PTS IN GERMANY: A RETROSPECTIVE SURVEY IN PRIVATE ONCOLOGY PRACTICES (Franke G-N et al.) • P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA (García-Gutiérrez V et al.) • P681: MATCHING-ADJUSTED INDIRECT COMPARISON OF ASCIMINIB VERSUS OTHER TYROSINE KINASE INHIBITORS IN THIRD-OR-LATER LINE CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (Atallah E et al.) • P683: TRIALS IN PROGRESS: FIRST-IN-HUMAN STUDY OF ELVN-001, A SELECTIVE BCR::ABL1 TYROSINE KINASE INHIBITOR, IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WHO FAILED PREVIOUS TYROSINE KINASE INHIBITOR THERAPIES (Collins H et al.) • P684: A MULTICENTER RETROSPECTIVE STUDY IN CHINA: CLINICAL CHARACTERISTICS

Time slots	Sessions
	<p>AND PROGNOSIS OF PATIENTS WITH CML-CP TREATED WITH DIFFERENT TYROSINE KINASE INHIBITORS (Huang J et al.)</p> <ul style="list-style-type: none"> • P685: LATE PHASE BCR-ABL DECLINE PREDICTS THE DURATION OF TKI (IMATINIB) FOR SUCCESSFUL TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA (Chethan R et al) • P686: REAL-WORLD EFFICACY PROFILE OF ASCIMINIB IN AN ITALIAN, MULTI-RESISTANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENT POPULATION (Breccia M et al.) • P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA (Bidikian A et al.) • P688: ASC2ESCALATE: A US PHASE 2, OPEN-LABEL, SINGLE-ARM, DOSE-ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND-LINE (2L) TREATMENT OF PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) (Atallah E et al.) • P737: LENZILUMAB AND AZACITIDINE IMPROVE HEMATOLOGIC ALTERATIONS OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN THE PREACH-M TRIAL (Ross D et al.)
For publication only	
CML – Biology and Translational Research	<ul style="list-style-type: none"> • PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY (Bernardi S et al) • PB1960: SARS-COV-2 OMICRON VARIANT INFECTION AND COVID-19 IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA IN CHINA (Li W et al.) • PB1961: INVOLVEMENT OF IMMUNITY IN THE CONTINUATION OF TFR AFTER BOSTINIB DISCONTINUATION (Fujioka Y et al.) • PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI (Marce Torra S et al.) • PB1963: PSYCHIATRIC DISORDERS AS A FIRST MANIFESTATION OF SPORADIC

Time slots	Sessions
	<p>CREUTZFELDT-JACOB DISEASE IN A PATIENT WITH CHRONIC MYELOID LEUKEMIA ON IMATINIB: UNUSUAL AND LIFE THREATENING ASSOCIATION (Smaili R et al.)</p>
CML - Clinical	<ul style="list-style-type: none"> • P1966: THE EFFECT OF BODY MASS INDEX ON THE SAFETY OF BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POST HOC POOLED DATA ANALYSIS (Isfort S et al.) • P1967: EVALUATION OF A TRIAL OF IMATIB* DOSE TAPERING IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: RESULTS AT 4.5 YEARS (Abdennebi N et al.) • P1968: IMPACTS ON OUTCOMES AND A PREDICTIVE MODEL OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL NILOTINIB-THERAPY (Li Z et al.) • P1969: PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND CORONAVIRUS DISEASE 2019 IN THE OMICRON ERA (Qi F et al.) • P1970: LONG-TERM RESULTS OF THERAPY FOR CHRONIC MYELOID LEUKEMIA: A 20-YEAR ANALYSIS OF THE GIPAP PROGRAM IN RUSSIA (Shukhov O et al.) • P1971: A PHASE 1 MULTICENTER OPEN-LABEL DOSE-ESCALATION AND DOSE-EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, EFFICACY OF HS-10382 (TERN-70) IN CHRONIC MYELOID LEUKEMIA PATIENTS (Li W et al.) • P1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE (Hochhaus A et al.) • P1973: MOLECULAR PATTERNS OF RESPONSE AFTER FRONTLINE TREATMENT IN CHRONIC MYELOID LEUKAEMIA (CML) (Fernandez-Leyva H et al.) • P1974: COMPARABLE B2A2/E13A2 AND B3A2/E14A2 REPORTING IN BCR-ABL ASSAY WHEN CALIBRATED BY WHO IS AND BY IVT-RNA COPY NUMBER (Wei H et al.) • P1975: ABL1 GENE DNA SEQUENCING IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (Kuzmina E et al.) • P1976: SINGLE CENTER STUDY ON SARS-COV-2 INFECTION IN PATIENTS AFFECTED BY

Time slots	Sessions
	<p>CML: VACCINATION STATUS AND BOSUTINIB THERAPY AS POSSIBLE PROTECTIVE FACTORS FOR HOSPITALIZATION (Civettini I et al.)</p> <ul style="list-style-type: none"> • P1977: EVALUATION OF ANTIBODY RESPONSES AMONG FIVE DIFFERENT SARS-COV-2 VACCINES IN CHRONIC MYELOID LEUKEMIA PATIENTS – A REAL-WORLD STUDY (Toreli AC et al.) • P1978: PATIENT-CENTREDNESS IS PIVOTAL IN A PROSPECTIVE DOSE REDUCTION TRIAL OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (Djodikromo M et al.) • P1979: DATA INTEGRATION BETWEEN CLINICAL RESEARCH AND PATIENT CARE: A FRAMEWORK FOR CONTEXT-DEPENDING DATA SHARING AND IN SILICO PREDICTIONS (Roeder I et al.) • P1980: ASC4KIDS: A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO DETERMINE THE DOSE AND SAFETY OF ASCIMINIB IN PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (Hijjya N eta l.) • P1981: EXPERIENCE OF FOUR LABORATORIES OF THE ITALIAN CML LABNET NETWORK IN THE USE OF THE CEPHEID CARTRIDGE SYSTEM (Izzo B et al.) • P1982: EPIDEMIOLOGICAL, CLINICAL AND THERAPEUTIC FEATURES OF CHRONIC MYELOID LEUKEMIA : EXPERIENCE OF FATTOUMA BOURGUIBA HOSPITAL OF MONASTIR (Lakhel S et al.) • P1983: RELATIONSHIP BETWEEN REGULAR MOLECULAR MONITORING AND TREATMENT OUTCOMES IN CML PATIENTS IN ARMENIA (Harutyunyan L et al.) • P1984: FACTORS ASSOCIATED WITH PROGRESSION-FREE SURVIVAL IN CHRONIC MYELOID LEUKEMIA PATIENTS ATTENDED AT FOSCAL IN THE PERIOD 2013-2020 (Sossa C et al.) • P1985: FACTORS ASSOCIATED WITH TOLERANCE TO PHARMACOLOGICAL THERAPY USING TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS ATTENDED AT FOSCAL IN THE PERIOD 2013-2020 (Sossa C et al.) • P1986: FIRST-LINE TREATMENT OUTCOMES OF CHRONIC MYELOID LEUKEMIA (CML)

Time slots	Sessions
	<p>PATIENTS IN A REAL-WORLD DATA SETTING IN LEBANON (Nasr L et al.)</p> <ul style="list-style-type: none"> • P1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS (Boughherira S et al.) • P1988: EXTRAMEDULLARY BLAST CRISIS PRESENTING AS INFILTRATIVE OPTIC NEURITIS: A TREATMENT DILEMMA (Lina J et al.)